Kallum Titchmarsh
Stock Analyst at Morgan Stanley
(4.22)
# 1,505
Out of 4,683 analysts
199
Total ratings
62.6%
Success rate
12.7%
Average return
Main Sectors:
Stocks Rated by Kallum Titchmarsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STVN Stevanato Group | Rated: Hold | $20 | $22.38 | -10.63% | 12 | Aug 24, 2026 | |
| HTFL HeartFlow | Maintained: Hold | $35 → $40 | $48.94 | -18.27% | 2 | Aug 17, 2026 | |
| A Agilent Technologies | Rated: Buy | $160 → $175 | $155.08 | +12.84% | 7 | Aug 13, 2026 | |
| NTRA Natera | Rated: Buy | $310 → $355 | $338.45 | +4.89% | 6 | Aug 10, 2026 | |
| TXG 10x Genomics | Rated: Hold | $37 → $40 | $64.26 | -37.75% | 7 | Aug 10, 2026 | |
| CRL Charles River Laboratories International | Rated: Buy | $260 → $300 | $295.10 | +1.66% | 7 | Aug 6, 2026 | |
| WAT Waters | Rated: Hold | $390 → $430 | $414.17 | +3.82% | 5 | Aug 6, 2026 | |
| CTKB Cytek Biosciences | Maintained: Hold | $5.5 | $4.57 | +20.35% | 3 | Aug 6, 2026 | |
| MTD Mettler-Toledo International | Rated: Hold | $1,275 → $1,450 | $1,398.46 | +3.69% | 5 | Aug 4, 2026 | |
| VCYT Veracyte | Rated: Sell | $47 → $44 | $44.29 | -0.65% | 6 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $175 → $185 | $170.92 | +8.24% | 7 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $220 | $215.36 | +2.15% | 9 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $10 → $14 | $14.50 | -3.45% | 2 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $20 → $22 | $26.16 | -15.90% | 5 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $200 → $240 | $261.51 | -8.23% | 6 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $620 → $650 | $633.71 | +2.57% | 5 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $70 | $68.48 | +2.22% | 5 | Jul 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $325 → $365 | $349.92 | +4.31% | 9 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $9 → $13 | $17.08 | -23.89% | 4 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 | $19.49 | -2.51% | 2 | Jun 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $60 | $79.59 | -24.61% | 5 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $100 → $68 | $83.10 | n/a | 6 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $200 → $182 | $61.80 | n/a | 12 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $130 → $160 | $119.15 | n/a | 15 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $20 → $15 | $4.96 | n/a | 11 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $10 | $4.72 | n/a | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $19.43 | n/a | 3 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $260 | $323.05 | n/a | 12 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $10 → $11 | $9.42 | n/a | 4 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 → $4 | $8.37 | n/a | 14 | Dec 3, 2024 |
Stevanato Group
Aug 24, 2026
Rated: Hold
Price Target: $20
Current: $22.38
Upside: -10.63%
HeartFlow
Aug 17, 2026
Maintained: Hold
Price Target: $35 → $40
Current: $48.94
Upside: -18.27%
Agilent Technologies
Aug 13, 2026
Rated: Buy
Price Target: $160 → $175
Current: $155.08
Upside: +12.84%
Natera
Aug 10, 2026
Rated: Buy
Price Target: $310 → $355
Current: $338.45
Upside: +4.89%
10x Genomics
Aug 10, 2026
Rated: Hold
Price Target: $37 → $40
Current: $64.26
Upside: -37.75%
Charles River Laboratories International
Aug 6, 2026
Rated: Buy
Price Target: $260 → $300
Current: $295.10
Upside: +1.66%
Waters
Aug 6, 2026
Rated: Hold
Price Target: $390 → $430
Current: $414.17
Upside: +3.82%
Cytek Biosciences
Aug 6, 2026
Maintained: Hold
Price Target: $5.5
Current: $4.57
Upside: +20.35%
Mettler-Toledo International
Aug 4, 2026
Rated: Hold
Price Target: $1,275 → $1,450
Current: $1,398.46
Upside: +3.69%
Veracyte
Aug 4, 2026
Rated: Sell
Price Target: $47 → $44
Current: $44.29
Upside: -0.65%
Aug 4, 2026
Rated: Buy
Price Target: $175 → $185
Current: $170.92
Upside: +8.24%
Aug 3, 2026
Maintained: Buy
Price Target: $220
Current: $215.36
Upside: +2.15%
Jul 30, 2026
Maintained: Hold
Price Target: $10 → $14
Current: $14.50
Upside: -3.45%
Jul 30, 2026
Maintained: Hold
Price Target: $20 → $22
Current: $26.16
Upside: -15.90%
Jul 29, 2026
Maintained: Hold
Price Target: $200 → $240
Current: $261.51
Upside: -8.23%
Jul 24, 2026
Maintained: Buy
Price Target: $620 → $650
Current: $633.71
Upside: +2.57%
Jul 10, 2026
Maintained: Buy
Price Target: $70
Current: $68.48
Upside: +2.22%
Jul 9, 2026
Rated: Hold
Price Target: $325 → $365
Current: $349.92
Upside: +4.31%
Jul 9, 2026
Rated: Hold
Price Target: $9 → $13
Current: $17.08
Upside: -23.89%
Jun 5, 2026
Maintained: Buy
Price Target: $19
Current: $19.49
Upside: -2.51%
May 12, 2026
Maintained: Hold
Price Target: $60
Current: $79.59
Upside: -24.61%
Jul 15, 2025
Maintained: Buy
Price Target: $100 → $68
Current: $83.10
Upside: n/a
Jul 15, 2025
Maintained: Buy
Price Target: $200 → $182
Current: $61.80
Upside: n/a
Jun 11, 2025
Maintained: Buy
Price Target: $130 → $160
Current: $119.15
Upside: n/a
May 20, 2025
Maintained: Hold
Price Target: $20 → $15
Current: $4.96
Upside: n/a
May 9, 2025
Maintained: Hold
Price Target: $10
Current: $4.72
Upside: n/a
May 6, 2025
Reiterated: Buy
Price Target: $19
Current: $19.43
Upside: n/a
Apr 24, 2025
Maintained: Hold
Price Target: $260
Current: $323.05
Upside: n/a
Feb 27, 2025
Maintained: Hold
Price Target: $10 → $11
Current: $9.42
Upside: n/a
Dec 3, 2024
Maintained: Hold
Price Target: $5 → $4
Current: $8.37
Upside: n/a